Roche's Polivy ADC Is Approved As Another New Option For R/R DLBCL

The first-in-class anti-CD79b antibody-drug conjugate received a swift accelerated approval by the US FDA based on the results of a Phase Ib/II trial, for the same setting as CAR-T agents.

A young man' hand is displaying a thumbs up, indicating that he likes or approves of something - Image

Roche is launching Polivy (polatuzumab vedotin-piiq) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in the US with an aim to move the first-in-class antibody-drug conjugate (ADC) into the front-line setting.

The anti-CD79b ADC was granted an accelerated approval from the FDA on 10 June based on the results of a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

PTC Projects Confidence In Sephience Launch With Royalty Buyback

 
• By 

The company will start shipping its newly launched phenylketonuria drug within two weeks and has bought back global net sales obligations for the treatment.

Jazz’s Modeyso Approved For Rare Glioma With Expansion Targeted

 

The accelerated approval came three months after Jazz completed the acquisition of Modeyso’s developer, Chimerix.

S&E In Brief: Launch Trends And Regulatory Updates Among SMID Biopharmas

 

Ultragenyx updated investors on interactions with the US FDA on gene therapy, while new drug launches were themes for Ionis and Organon in Q2 reporting.

Pipeline Watch: Ten Approvals And Fourteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

PTC Projects Confidence In Sephience Launch With Royalty Buyback

 
• By 

The company will start shipping its newly launched phenylketonuria drug within two weeks and has bought back global net sales obligations for the treatment.

Executives On The Move: Changes At The Top At Novo Nordisk Plus Other New CEOs

Flashpoint Therapeutics and Nerviano Medical Sciences (Shanghai) have new leaders, while Genmab hires an ex-Gilead Sciences executive.

Lilly Confident In Orforglipron Despite Disappointing Phase III Data

 
• By 

Lilly spent much of its earnings call defending orforglipron as analysts lamented its results in obesity versus Novo’s semaglutide, overshadowing strong Q2 revenue growth driven by existing GLP-1/GIP franchise Mounjaro/Zepbound.